July 16, 2020
NIH, Moderna’s COVID-19 vaccine headed to Phase III trial
Editor's Note
Researchers testing a COVID-19 vaccine being developed by Dr Anthony Fauci’s team at the National Institutes of Health (NIH) and Moderna Inc, reported July 14 that the vaccine was able to produce neutralizing antibodies in the 45 trial participants inoculated in March.
Moderna is scheduled to launch a late-stage trial to evaluate the vaccine in 30,000 volunteers at the end of July.
Free Daily News
- Trump vs. Harris: Key differences in healthcare proposals for Medicaid, Medicare, private insurance, abortion
- Updated AAMI standard addresses chemical sterilization safety, compliance
- Study: Stool tests show promise in reducing colonoscopies for post-polypectomy colorectal cancer surveillance
- Healthcare employment up in October
- Save the date for OR Manager Conference 2025
- Session: Staff resilience during extended downtime
- Session: Managing difficult conversations—How to respond effectively to your team
- Closing Keynote: The fire within—The art of bold self leadership
- Session: The case for disrupting, revolutionizing OR, SPD education
- Session: What talented nurses want from potential employers
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement